Status:
WITHDRAWN
Inter-Assay Growth Hormone and IGF-I Variability
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Acromegaly
Growth Hormone Deficiency
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to demonstrate the degree of variability in commercially available assays for Growth Hormone measurement in the context of clinical decision making for Growth Hormone (GH)...
Detailed Description
This research will explore the variability of GH and IGF-1 measurements by commercially available tests. The hypothesis is that the variability in GH and IGF-1 measurement will be sizable enough that ...
Eligibility Criteria
Inclusion
- Male or Female age 18+
- Clinical indication for testing GH response to secretagogue testing to evaluate for GHD OR clinical indication for testing for GH response to oral glucose load (75grams of glucose) to evaluate for Acromegaly either for diagnosis OR normal volunteer for control group.
- Normal volunteers will be screened for evidence of pituitary endocrine dysfunction prior to Oral Glucose Tolerance Testing (OGTT) and Growth Hormone Releasing Hormone - Arginine Testing (GHRH-ARG).
- Able to provide informed consent
Exclusion
- Subjects taking GH
- Pregnant or breast feeding
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00638287
Start Date
November 1 2007
End Date
January 1 2011
Last Update
October 6 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.